Alexander A. Fitzpatrick

Filings by Alexander A. Fitzpatrick span 2 companies, the busiest being Evofem Biosciences, Inc. and ARS Pharmaceuticals, Inc. We count 8 filings; the first trade dates from 20 May 2021 and the latest from 12 June 2026.

The open-market side counts 3 purchases for €154k alongside 1 sale. The amount is not disclosed for 1 filing. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 2 share grants and 1 option exercise. In 2026 alone, the filings show no purchases and 1 sale.

Half of the purchases are above €8,649 and half below. 3 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster.

The newest entry dates from 12 June 2026: an open-market sale, in ARS Pharmaceuticals, Inc. The clock since the last published purchase (2 October 2023) now reads 1,112 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.